Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

PsyPal Psilocybin Therapy for Psychological Distress in Palliative Care Patients

Coordinator
Academisch Ziekenhuis Groningen, Netherlands
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€6.5m
Total cost
€6.5m
Partners
20 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101137378

What the project is doing

In the project's own words, from its summary on CORDIS.

Relieving serious health-related suffering for patients in palliative and end-of-life care, be it physical, psychological, social, or spiritual, is a global ethical responsibility. However, the profound psycho-emotional and existential distress entailed by such suffering, despite often being an enormous burden for both patients and their loved ones, remains a field largely overlooked by health care providers and the scientific community.

Those people may develop mood or anxiety disorder for which neither non-pharmacological nor pharmacological interventions exist. In this context, we believe it is now time to target these unmet needs in the palliative care population. We want to initiate a paradigm shift at the boundaries between palliative care, psychiatry, psychology, neuroscience, and spiritual care. Our starting point is the preliminary results being reported for administration of psilocybin, the main psychoactive compound of so-called ‘psychedelic mushrooms’, in patients with depression.

The objective of our project is thus to examine the clinical effect of a cutting-edge, individualised and patient-centred, open and standardised Psilocybin Therapy, addressing these unmet needs of patients in palliative care. We will show high quality evidence via a multi-centre Randomised Clinical Trial of the value of our therapeutic model in patients (and for the following four conditions: COPD, Atypical Parkinsonian Disorders, ALS, and Multiple Sclerosis), their loved ones and care providers, in a diverse sample of the European population, in addition to better understand the mechanisms of therapeutic change of our model.

Finally, our project will establish a sustainable, multi-disciplinary, ecosystem of key European stakeholders jointly contributing to the medical use of psychedelic research and innovation, paving the way towards an ethical and cost-effective deployment of such a new line of care for patients in European palliative care service providers.

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis GroningenGroningenNetherlandsCoordinator
European Association for Palliative CareVilvoordeBelgiumParticipant
European Federation of Neurological AssociationsBrusselsBelgiumParticipant
Narodni Ustav Dusevniho ZdraviKlecanyCzechiaParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Universidad De NavarraPamplonaSpainParticipant
Association Europeenne De PsychiatrieStrasbourgFranceParticipant
Centre Expert En Technologies Et Services Pour Le Maintien En Autonomie a Domicile Des Personnes AgeesRosiere Pres TroyesFranceParticipant
Long Alliantie NederlandAmersfoortNetherlandsParticipant
Rijksuniversiteit GroningenGroningenNetherlandsParticipant
Stichting Open: Onderzoek Naar De Psychedelische Ervaring NederlandAmsterdamNetherlandsParticipant
Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez ChampalimaudLisboaPortugalParticipant
A+ Science ABStockholmSwedenParticipant
Ctc Clinical Trial Consultants ABUppsalaSwedenParticipant
Osmond Labs ABUppsalaSwedenParticipant
Stiftelsen 29k FoundationStockholmSwedenParticipant
Stiftelsen Norrsken MindStockholmSwedenParticipant
Stockholms UniversitetStockholmSwedenParticipant
Uppsala UniversitetUppsalaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI